AAM
TEVA icon

Advisors Asset Management’s Teva Pharmaceuticals TEVA Stock Holding History

Advisors Asset Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$843K Buy
24,884
+6,355
+34% +$212K 0.01% 848
2026
Q1 		$558K Buy
18,529
+11,658
+170% +$375K 0.01% 934
2025
Q4 		$214K Buy
6,871
+3,073
+81% +$75.7K ﹤0.01% 1122
2025
Q3 		$76.7K Buy
3,798
+1,362
+56% +$23.9K ﹤0.01% 1250
2025
Q2 		$40.8K Buy
+2,436
New +$39.3K ﹤0.01% 1299
2021
Q1 		– Sell
-1,281
Closed -$12K – 1528
2020
Q4 		$12K Sell
1,281
-5,035
-80% -$48.2K ﹤0.01% 1498
2020
Q3 		$56.9K Sell
6,316
-789
-11% -$8.35K ﹤0.01% 1390
2020
Q2 		$88K Sell
7,105
-527
-7% -$5.96K ﹤0.01% 1325
2020
Q1 		$68.5K Sell
7,632
-148
-2% -$1.52K ﹤0.01% 1275
2019
Q4 		$76.2K Sell
7,780
-52
-0.7% -$464 ﹤0.01% 1353
2019
Q3 		$53.9K Buy
7,832
+41
+0.5% +$314 ﹤0.01% 1391
2019
Q2 		$71.9K Buy
7,791
+1,496
+24% +$18K ﹤0.01% 1357
2019
Q1 		$98.7K Sell
6,295
-3,802
-38% -$67K ﹤0.01% 1323
2018
Q4 		$156K Sell
10,097
-461
-4% -$9.45K ﹤0.01% 1253
2018
Q3 		$227K Sell
10,558
-19,287
-65% -$448K ﹤0.01% 1221
2018
Q2 		$726K Sell
29,845
-4,127
-12% -$84.2K 0.01% 944
2018
Q1 		$636K Sell
33,972
-679
-2% -$13.3K 0.01% 1001
2017
Q4 		$657K Sell
34,651
-4,249
-11% -$63.9K 0.01% 1002
2017
Q3 		$685K Buy
38,900
+5,470
+16% +$123K 0.01% 982
2017
Q2 		$1.11M Buy
33,430
+9,136
+38% +$283K 0.02% 843
2017
Q1 		$780K Buy
24,294
+643
+3% +$21.9K 0.01% 947
2016
Q4 		$857K Sell
23,651
-1,520
-6% -$60.7K 0.01% 940
2016
Q3 		$1.16M Buy
25,171
+889
+4% +$46.4K 0.02% 810
2016
Q2 		$1.22M Sell
24,282
-3,190
-12% -$170K 0.02% 816
2016
Q1 		$1.47M Sell
27,472
-1,569
-5% -$92.1K 0.02% 738
2015
Q4 		$1.91M Sell
29,041
-10,148
-26% -$627K 0.03% 673
2015
Q3 		$2.21M Sell
39,189
-181
-0.5% -$11.7K 0.04% 593
2015
Q2 		$2.33M Sell
39,370
-47,828
-55% -$2.95M 0.03% 617
2015
Q1 		$5.43M Sell
87,198
-38,834
-31% -$2.26M 0.07% 347
2014
Q4 		$7.25M Sell
126,032
-44,932
-26% -$2.5M 0.1% 264
2014
Q3 		$9.19M Sell
170,964
-29,817
-15% -$1.58M 0.13% 211
2014
Q2 		$10.5M Buy
200,781
+5,521
+3% +$282K 0.15% 189
2014
Q1 		$10.3M Buy
195,260
+41,444
+27% +$1.92M 0.16% 180
2013
Q4 		$6.17M Buy
153,816
+43,836
+40% +$1.73M 0.1% 269
2013
Q3 		$4.16M Buy
109,980
+44,919
+69% +$1.75M 0.07% 330
2013
Q2 		$2.55M Buy
+65,061
New +$2.53M 0.05% 417

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Advisors Asset Management's TEVA Position: Q2 2026 in Review

Advisors Asset Management increased its Teva Pharmaceuticals (TEVA) stake by 34% in Q2 2026, buying an estimated $212K and bringing the position to 24,884 shares worth $843K. The position accounts for 0.01% of the portfolio, ranked #848.

Advisors Asset Management first reported a position in TEVA in Q2 2013 and has held it in 36 quarters since. The position peaked at $10.5M in Q2 2014. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Advisors Asset Management held 24,884 shares of Teva Pharmaceuticals worth $843K as of Q2 2026.
  • Advisors Asset Management bought 6,355 Teva Pharmaceuticals shares in Q2 2026, an estimated $212K.
  • Teva Pharmaceuticals made up 0.01% of Advisors Asset Management's portfolio in Q2 2026, its #848 holding.
  • Advisors Asset Management first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 36 quarters since.
  • Advisors Asset Management's Teva Pharmaceuticals position peaked at $10.5M in Q2 2014.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Advisors Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.